Coherus Oncology Inc (CHRS) FinancialsCHRSCoherus Oncology Inc

Coherus Oncology Inc (CHRS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is LOQTORZI, accounting for 95.1% of total sales, equivalent to $13.61M. Another important revenue stream is Other. Understanding this composition is critical for investors evaluating how CHRS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Coherus Oncology Inc maintains a gross margin of 70.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -225.98%, while the net margin is -233.08%. These profitability ratios, combined with a Return on Equity (ROE) of -178.39%, provide a clear picture of how effectively CHRS converts its operational activities into shareholder value.

In the context of the broader market, CHRS competes directly with industry leaders such as KROS and SIGA. With a market capitalization of $224.03M, it holds a leading position in the sector. When comparing efficiency, CHRS's gross margin of 70.35% stands against KROS's 100.00% and SIGA's 57.17%. Such benchmarking helps identify whether Coherus Oncology Inc is trading at a premium or discount relative to its financial performance.

Coherus has demonstrated increasing total revenue, with Q2 2026 revenue reaching $14.31 million, up from $12.31 million in Q1 2026. The gross margin has also improved consistently, reaching 70.35% in Q2 2026, reflecting strong operational efficiency.